Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
7 shown of 2,300 total abstracts
  1. Abstract 62742026-09-04 · 20:45 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    P. Schmid, L. Paz-Ares, R. Herbst · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 66592026-09-04 · 19:45 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    R. Herbst, E. Winer · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 65812026-09-04 · 18:45 CT · S406
    Quality of life outcomes with Keytruda in patients with RCC
    R. Herbst, H. Rugo, F. Andre, et al. · Stanford Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 61762026-09-05 · 19:30 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-415 study)
    S. Modi, F. Andre · Cleveland Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 62492026-09-02 · 19:15 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-435
    R. Herbst, S. Peters, C. Robert · Dana-Farber Cancer Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 67142026-09-03 · 20:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-899 study)
    N. Rizvi, H. Rugo · National Cancer Center Japan
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 63802026-09-01 · 18:45 CT · S406
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-618
    S. Modi, J. Cortes, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.